Dyadic International (DYAI) Net Income towards Common Stockholders Growth (3y) (2021 - 2026)
Powered by 
Analysis
Dyadic International (DYAI) Net Income towards Common Stockholders Growth (3y) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.67 Bn | 192.69 Bn | 7.24 Bn | 19.87% |
| 2 | Gilead Sciences | 180.06 Bn | 176.88 Bn | 6.22 Bn | -129.59% |
| 3 | Vertex Pharmaceuticals | 131.44 Bn | 123.59 Bn | 2.84 Bn | 6.30% |
| 4 | Regeneron Pharmaceuticals | 81.94 Bn | 73.95 Bn | 3.93 Bn | 10.23% |
| 5 | Argenx Se | 60.28 Bn | 55.10 Bn | 1.37 Bn | 91.31% |
| 6 | Moderna | 53.87 Bn | 48.73 Bn | 52.00 Mn | 17.25% |
| 7 | Alnylam Pharmaceuticals | 33.15 Bn | 29.85 Bn | 992.69 Mn | 37.44% |
| 8 | Biogen | 31.88 Bn | 30.60 Bn | 1.96 Bn | -45.23% |
| 9 | Roivant Sciences | 29.16 Bn | 29.16 Bn | 1.16 Mn | - |
| 10 | Dyadic International | 18.24 Mn | 10.27 Mn | - | 0.62% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 0.62% |
| Dec 31, 2025 | 10.86% |
| Sep 30, 2025 | -2.49% |
| Jun 30, 2025 | 18.66% |
| Mar 31, 2025 | 9.93% |
| Dec 31, 2024 | 28.89% |
| Sep 30, 2024 | 63.30% |
| Jun 30, 2024 | 19.68% |
| Mar 31, 2024 | 91.45% |
| Dec 31, 2023 | -1.86% |
| Sep 30, 2023 | 13.56% |
| Jun 30, 2023 | 6.30% |
| Mar 31, 2023 | 4.22% |
| Dec 31, 2022 | -7.28% |
| Sep 30, 2022 | -2.13% |
| Jun 30, 2022 | -6.84% |
| Mar 31, 2022 | -8.02% |
| Dec 31, 2021 | -101.86% |
| Sep 30, 2021 | -29.21% |
| Jun 30, 2021 | -34.05% |